EUVIMEDEUVIMED entdecken
Crossref

Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England

Sunyoung Choi, Mohamed Mortagy iD, Ker Shiong Tan, Benjamin E White, Sangeeta Paisey, Aya Abdelhameed, Brian Rous, John Ramage iD

Endocrine-Related Cancer · 2026

DOI: 10.1530/erc-26-0268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Sunyoung Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hampshire Hospitals NHS Foundation Trust , Basingstoke, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine prostate cancer (NEPC) is a rare and aggressive variant of prostate cancer (PC) that can be de novo (d-NEPC) or transform from prior prostate adenocarcinoma (PCa) as treatment-emergent NEPC (t-NEPC). This study aimed to study the clinical characteristics and overall survival (OS) of NEPC using data from the SEER and NCRAS registries and to compare OS of d-NEPC and t-NEPC. A total of 1,465 patients with NEPC were extracted from SEER (n = 990, 2010–2022) and NCRAS (n = 475, 2010–2021). Patients were classified as t-NEPC if preceded by a documented PCa. The primary outcome was OS measured from the date of NEPC diagnosis. Kaplan–Meier analysis, the log-rank test, and Cox regression were performed for SEER, NCRAS, and pooled cohorts. t-NEPC represented 9.9% in NCRAS and 15.2% in SEER. Small cell carcinoma was the most common subtype (80.2% NCRAS, 74.7% SEER). Median time to transformation was 4.63 years in NCRAS and 5 years in SEER. In the pooled cohort, median OS was 9 months for d-NEPC and 7 months for t-NEPC (log-rank P < 0.001). The 60-month OS was 7.9% for d-NEPC and 4.0% for t-NEPC. In the pooled multivariable Cox regression, t-NEPC was independently associated with worse OS (aHR: 1.30, 95% CI: 1.11–1.53, P = 0.001). Data source was not associated with OS (aHR: 1.08, P = 0.206), indicating comparable OS between the USA and England. In this bi-national, population-based study, t-NEPC was associated with worse OS than d-NEPC. OS for NEPC was comparable between the USA and England. These findings support distinguishing d-NEPC from t-NEPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCarcinoma, NeuroendocrineNeuroendocrine TumorsHumansMaleUnited StatesEnglandAgedMiddle AgedSEER Program

Stichwörter der Autor:innen

de novoprostate adenocarcinomaprostate neuroendocrine carcinomasmall cellsurvivaltransformed

Autor:innen und Institutionen

  • Hampshire Hospitals NHS Foundation Trust , Basingstoke, United Kingdom.
  • St. George's University School of Medicine , St George's, Grenada.
  • Cambridge University Hospitals NHS Foundation Trust , Cambridge, United Kingdom.
  • University of Winchester , Winchester, United Kingdom.
  • King's Health Partners Neuroendocrine Tumour Centre , London, United Kingdom.

ORCID-Profile: Mohamed Mortagy, John Ramage

Zitieren

APA

Choi, S., Mortagy, M., Tan, K. S., White, B. E., Paisey, S., Abdelhameed, A., Rous, B., & Ramage, J. (2026). Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England. Endocrine-Related Cancer. https://doi.org/10.1530/erc-26-0268

Vancouver

Choi S, Mortagy M, Tan KS, White BE, Paisey S, Abdelhameed A, et al. Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England. Endocrine-Related Cancer. 2026. doi:10.1530/erc-26-0268

BibTeX
@article{Choi2026,
  author = {Choi, Sunyoung and Mortagy, Mohamed and Tan, Ker Shiong and White, Benjamin E and Paisey, Sangeeta and Abdelhameed, Aya and Rous, Brian and Ramage, John},
  title = {Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  doi = {10.1530/erc-26-0268}
}
Kostenlos starten →